PharmD · New Jersey
Collaborative Drug Therapy Management for Pharmacists in New Jersey
Yes, a written agreement with a physician is required before you manage drug therapy. New Jersey calls it a Written Protocol.
Represents NJ's pharmacist drug-therapy-management Collaborative Practice Agreement (CPA) tier (N.J.S.A. 45:14-61; N.J.A.C. 13:35-6.27), not ordinary dispensing licensure, which needs no physician agreement and is out of scope here. Naloxone prescribing (2023 law) and self-administered hormonal contraceptives (N.J.S.A. 45:14-67.9, via a statewide Board of Pharmacy/BME-approved protocol) are separate authorities that do NOT require an individual CPA with a specific physician — see the note under Written agreement.
What the collaboration must look like
The rules the physician relationship has to follow. Each fact comes from the statute or board rule listed under sources.
Proximity
Not codified — left to the agreement
Supervision ratio
Not codified — no cap on file
Chart review
Percentage set by agreement · Annually
No fixed chart-review percentage is codified — the collaborating physician must 'establish a method for monitoring both compliance with the collaborative practice agreement and clinical outcomes,' with the protocol itself reviewed at least annually (N.J.A.C. 13:35-6.27). Percentage is therefore omitted rather than set to 0.
Meeting cadence
Annually
Each protocol must be reviewed at least once per year by the physician and pharmacist to determine whether it should be renewed, modified, or terminated (N.J.A.C. 13:35-6.27); no in-person format is specified.
Prescriptive authority
Covered by the practice agreement · no controlled-substance authority
Physician notification timing, chart-update interval, and a protocol-change notice window must all be specified in the protocol itself — no statewide default is fixed.
Written agreement
Required
True for the drug-therapy-management CPA tier this entry represents. But naloxone dispensing and hormonal-contraceptive furnishing are authorized under separate, statewide standardized protocols rather than a per-pharmacist agreement with a named physician — a pharmacist can exercise those two authorities without entering any individual CPA at all.
Practice ownership (corporate practice of medicine)
Non-licensee ownership permitted — No statute identified restricting retail-pharmacy ownership to licensed pharmacists; assumed to follow the common pattern of corporate ownership with a designated pharmacist-in-charge, which should be confirmed for New Jersey
Materially more permissive than the medical-PC corporate-practice regime governing PAs, NPs, CRNAs, CNMs and CNSs.
Sources for the supervision rules (5)
- N.J.S.A. 45:14-61 — Pharmacy Practice Act, collaborative practice agreements
- N.J.A.C. 13:35-6.27 — Standards for collaborative practice for drug therapy management with licensed pharmacistssecondary
- N.J.S.A. 45:14-67.9 — Pharmacist furnishing of self-administered hormonal contraceptives
- N.J.A.C. 13:39-14.1 — Protocol for pharmacists furnishing self-administered hormonal contraceptivessecondary
- P.L. 2023, c.2 (S275) — pharmacist naloxone prescribing authority
What a collaborating physician costs here
Typical monthly cost in New Jersey
$500 – $600
Estimate for one Pharmacist. Standard-tier state.
About New Jersey's rules
S2996/A4052 (signed 3/30/2026) grants APNs in primary/behavioral-health population foci independent practice at ≥5,000 hours, ending the COVID-era waiver — but implementing regulations were not yet adopted at this writing, so several details below rely on bill text/press coverage, not a finalized rule. NJ's Professional Service Corporation Act (N.J.S.A. 14A:17-1 et seq.) is notably strict CPOM: only physicians may hold equity in a medical PC.
Other clinicians in New Jersey: see the state overview.